CA3201539A1 - Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists - Google Patents

Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists

Info

Publication number
CA3201539A1
CA3201539A1 CA3201539A CA3201539A CA3201539A1 CA 3201539 A1 CA3201539 A1 CA 3201539A1 CA 3201539 A CA3201539 A CA 3201539A CA 3201539 A CA3201539 A CA 3201539A CA 3201539 A1 CA3201539 A1 CA 3201539A1
Authority
CA
Canada
Prior art keywords
methods
gcgr
blood glucose
glp
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3201539A
Other languages
English (en)
French (fr)
Inventor
Vyjayanthi Krishnan
Joyce James
Omar OLHAYE
Matthew Scott Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spitfire Pharma LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3201539A1 publication Critical patent/CA3201539A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3201539A 2020-12-07 2021-12-07 Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists Pending CA3201539A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063122117P 2020-12-07 2020-12-07
US63/122,117 2020-12-07
US202163211157P 2021-06-16 2021-06-16
US63/211,157 2021-06-16
US202163249468P 2021-09-28 2021-09-28
US63/249,468 2021-09-28
PCT/US2021/062286 WO2022125598A1 (en) 2020-12-07 2021-12-07 Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists

Publications (1)

Publication Number Publication Date
CA3201539A1 true CA3201539A1 (en) 2022-06-16

Family

ID=81972768

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3201539A Pending CA3201539A1 (en) 2020-12-07 2021-12-07 Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists

Country Status (8)

Country Link
US (1) US20250134963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255564A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024500324A (cg-RX-API-DMAC7.html)
KR (1) KR20230129425A (cg-RX-API-DMAC7.html)
CA (1) CA3201539A1 (cg-RX-API-DMAC7.html)
IL (1) IL303512A (cg-RX-API-DMAC7.html)
MX (1) MX2023006736A (cg-RX-API-DMAC7.html)
WO (1) WO2022125598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250067161A (ko) * 2022-09-14 2025-05-14 스핏파이어 파마, 엘엘씨 Glp-1r 및 gcgr 효능제를 사용하여 지방간 질환을 앓는 피험체에서 체중을 감소시키기 위한 치료 요법 및 방법
WO2024098071A1 (en) * 2022-11-05 2024-05-10 Spitfire Pharma Llc Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist
IL328182A (en) * 2023-11-06 2026-07-01 Gan & Lee Pharmaceuticals Co Ltd GLP-1 receptor agonist for weight loss
US20250288650A1 (en) * 2024-03-12 2025-09-18 Spitfire Pharma Llc Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist
CN118477048B (zh) * 2024-05-24 2024-12-17 山东泰合医药科技有限公司 一种布瑞哌唑缓释微球及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
CN117582516A (zh) * 2014-05-28 2024-02-23 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
SG10202109721PA (en) * 2016-03-10 2021-10-28 Medimmune Ltd Glucagon and glp-1 co-agonists for the treatment of obesity
AU2019205905B2 (en) * 2018-01-03 2024-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of NASH and other disorders
US12441776B2 (en) * 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations

Also Published As

Publication number Publication date
JP2024500324A (ja) 2024-01-09
IL303512A (en) 2023-08-01
EP4255564A1 (en) 2023-10-11
KR20230129425A (ko) 2023-09-08
WO2022125598A1 (en) 2022-06-16
US20250134963A1 (en) 2025-05-01
EP4255564A4 (en) 2024-11-06
MX2023006736A (es) 2023-08-21

Similar Documents

Publication Publication Date Title
MX2023006736A (es) Regimenes y metodos terapeuticos para reducir la glucosa en sangre o el peso corporal usando agonistas balanceados de glp-1r y gcgr.
CN109476723B (zh) Ny-eso-1肿瘤抗原hla-a*02复合物的特异性t细胞受体
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
AU3322089A (en) Anti-t-cell receptor determinants as autoimmune disease treatment
JP2024113005A (ja) インターロイキン-2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
EP4470551A3 (en) Dual-target fusion proteins comprising the fc portion of an immunoglobulin
WO2024059753A3 (en) Therapeutic regimens and methods for reducing body weight in a subject with fatty liver disease using a glp-1r and gcgr agonist
Appel et al. Kinetics of T-cell receptor binding by bivalent HLA-DR· peptide complexes that activate antigen-specific human T-cells
WO2020076136A3 (ko) 아커만시아 뮤시니필라 균주 및 이의 용도
CN113840834B (zh) Magea1特异性t细胞受体及其用途
MX2022014090A (es) Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos.
MX349293B (es) Tratamiento de cancer con dosis elevadas de proteinas de fusion del receptor del factor de crecimiento de fibroblastos 1 (fgfr1) solubles.
US7758862B2 (en) Hepatocyte growth factor receptor splice variants and methods of using same
TW200531700A (en) Uses of melanocortin-4 receptor (MC4R) agonist peptides administered by continuous infusion
Lee et al. Expression and purification of intracrine human FGF 11 and study of its FGFR-dependent biological activity
Sanz-Soler et al. Recombinant expression of mutants of the Frankenstein disintegrin, RTS-ocellatusin. Evidence for the independent origin of RGD and KTS/RTS disintegrins
CA2832376C (en) Drug containing recombinant mistletoe lectins for treating malignant melanoma
Tanaka et al. Modification of the HER2/NEU‐derived tumor antigen GP2 improves induction of GP2‐reactive cytotoxic T lymphocytes
NO318912B1 (no) Interferon alfa/beta - bindingsprotein, samt fremstilling og anvendelse derav
Balzarini Large-molecular-weight carbohydrate-binding agents as HIV entry inhibitors targeting glycoprotein gp120
MX2025005071A (es) Regímenes terapéticos y métodos para el tratamiento de factores de riesgo cardiovascular utilizando un agonista del glp-1r y del gcgr
Liu et al. Novel design of interleukin-2 derivatives with reversed pH and potent antitumor activity
US10722553B2 (en) Medicament containing recombinant mistletoe lectins for the treatment of brain tumors
Kim et al. Functional identification of a protein inhibitor of neuronal nitric oxide synthase of Taenia solium metacestode
Hui et al. Expression and characterization of bifunctional fusion proteins possessing antitumor and thrombolytic function for targeting therapy

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241202

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241202

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251201

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251201

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251204

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260203

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205